The Central Council for Research in Siddha (CCRS) said it would soon start a clinical trial in order to find out the potential of Siddha medicine in the treatment of COVID19.
As per reports, a Siddha medicine Kabasurakudineer, which was used as an ‘add-on’ therapy to allopathic treatment at the COVID19 care centre in Chennai’s Government Stanley Medical College Hospital, had shown some positive results.
Kabasurakudineer is a herbal concoction, comprising dry ingredients of ginger, pippali, clove, cirukancori root and many other herbs.
To conduct the study, 60 asymptomatic, mild and moderate coronavirus positive patients would be admitted at the COVID-19 Care Centre established by Greater Chennai Corporation at Vysarpadi.
The organization is expecting to start conducting the clinical trials of the Siddha medicine from next week.
The new study is in sync with the directive issued by the Union Ayush Ministry and with the consent from the Tamil Nadu government.
CCRS is the apex body pertaining to research in Siddha system of Medicine.
It works towards the scientific validation of Siddha System of Medicine through clinical research, drug research, medicinal plants research, fundamental research, literary research and documentation.
The decision to conduct the clinical trial comes at a time when the number of coronavirus cases in the country have already increased to 5,48,318.
